[1]

[2]

SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.

[3]

LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.

[4]

YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.

[5]

XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.

[6]

CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.

[7]

. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.

[8]

. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.

[9]

[10]

YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.

[11]

DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.

[12]

GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.

[13]

. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.

[14]

. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.

[15]

. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

年龄（岁）	筛查例数	百分比（%）	HPV阳性例数	阳性检出率（%）
≤20	42	0.5	3	0.13
21 ~ 30	2 207	26.1	681	29.64
31 ~ 40	2 412	28.6	815	35.50
41 ~ 50	2 778	32.9	614	26.73
>51	1 006	11.9	184	8.00
合计	8 445	100.0	2 297	100.00

年龄（岁）	筛查例数	百分比（%）	HPV阳性例数	阳性检出率（%）
≤20	42	0.5	3	0.13
21 ~ 30	2 207	26.1	681	29.64
31 ~ 40	2 412	28.6	815	35.50
41 ~ 50	2 778	32.9	614	26.73
>51	1 006	11.9	184	8.00
合计	8 445	100.0	2 297	100.00

年龄（岁）	筛查例数	百分比（%）	HPV阳性例数	阳性检出率（%）
≤20	52	4.5	45	5.5
21 ~ 30	348	30.1	270	32.1
31 ~ 40	307	26.6	221	27.1
41 ~ 50	279	24.2	189	23.2
> 51	169	14.6	91	11.1
合计	1 155	100.00	816	100.0

RichHTML

PDF (PC)

[1]	ELISCU A.Human papillomavirus and HPV vaccines[J]. Pediatr Rev, 2017,38(9):443-445.
[2]	VINODHINI K, SHANMUGHAPRIYA S, DAS B C, et al.Prevalence and risk factors of HPV infection among women from various provinces of the world[J]. Arch Gynecol Obstet, 2012,285(3):771-777.
[3]	向秀华, 李丹, 田辉,等. 人乳头瘤病毒联合液基薄层细胞学检查与宫颈上皮内瘤变结果分析[J]. 实用医技杂志, 2016,23(9):949-950.
[4]	赵艳芳. 云南少数民族文化发展的思考[J]. 云南社会科学, 2008,S1:227-228.
[5]	杨志玲, 刘华, 吕瑜玫,等. 120例宫颈上皮内瘤变患者不同型别HPV感染状况分析[J]. 重庆医学,2016,45(4):475-477.
[6]	周建芳, 王玉霞. 妇科疾病患者HPV感染及其影响因素分析[J]. 中国公共卫生,2017,33(2):311-313.